Insulet releases 2021 sustainability report; highlights include 100% fulfillment of customer orders via dual and local sourcing while in Europe, UK, Canada, Insulet diverted over 135 metric tons of Omnipod Pods from landfills via product takeback programs

Sample article from our Health Care Sector

ACTON, Massachusetts , May 13, 2022 (press release) –

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the release of its 2021 Sustainability Report. The publication highlights the Company’s success in Environmental, Social, and Governance (ESG) issues across Insulet’s global markets and describes the progress Insulet has made in building upon its sustainability strategy.

“It is more important than ever to integrate sustainability into our business while pursuing our mission to simplify and improve the lives of people with diabetes worldwide,” said Shacey Petrovic, President and Chief Executive Officer. “We are now driving measurable impact on critical environmental, social, and governance issues. I am proud of the remarkable progress we have made in a short amount of time, and I know that our accomplishments will motivate continued growth.”

As described in the Sustainability Report, Insulet executed several purpose-driven projects designed to build resilient operations, drive sustainable product innovation, and expand the Company’s social impact while reducing its effect on the environment.

While supply chains around the world were disrupted in 2021, Insulet achieved 100% fulfillment of customer orders, due to the Company’s dual and local sourcing efforts. Throughout the year, Insulet built resilience by managing climate-related risks and opportunities, and making advancements in products, packaging, and operations that improve sustainability at all phases of the product’s lifecycle. For example, in the European Union, U.K., and Canada, more than 135 metric tons of Pods* were diverted from landfills through product takeback programs. With solar roof panels at its United States headquarters in Acton, Massachusetts, the Company generated almost 800 kilowatt hours of renewable energy.

Insulet continued to build an inclusive culture to foster employee wellbeing. The Company offered comprehensive, flexible working arrangements to support employees and expand the talent pool. Over 500 employees participated in our seven Employee Resource Groups, a two-fold increase in participation from our inaugural year in 2020. Additionally, aligned with its commitment to embed diversity, equity, and inclusion throughout all levels of Insulet, the Company reached 60% gender and ethnic diversity on its Board of Directors.

“As I reflect on our journey, we have much to be proud of, and there is more ahead to challenge and excite us,” said Lisa Brady, Vice President of Global Sustainability and Chief Sustainability Officer. “We remain inspired by our sustainability vision to ‘Deliver growth with purpose: Innovating to improve lives and preserve our planet,’ and we look forward to leading systemic change on key environmental, social, and economic issues.”

The 2021 report applies the Sustainability Reporting Standards issued by the Global Reporting Initiative (GRI), the most prevalent international standards used to report an organization’s sustainability impact and performance. This year’s report also continues to align with the Sustainability Accounting Standards Board (SASB). SASB is the leading standard used by investors and public companies to ensure standardization in reporting on ESG issues and specifically how they impact financial performance.

The full report can be found at investor.insulet.com under Environmental, Social & Governance.

* These metrics reflect data for the European Union, U.K., and Canada

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.

©2022 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005118/en/

Investor Relations:
Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
dgordon@insulet.com

Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com

Source: Insulet Corporation

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.